UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.   20549
Form 8-K/A
Current Report
___________________________________

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

Date of Report: November 4, 1996

Commission file number 0-20772

CYPROS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction of incorporation or
organization)

33-0476164
(I.R.S. Employer Identification No.)

2714 Loker Avenue West
Carlsbad, California                           92008
(Address of principal executive offices)     (Zip Code)

Registrant's telephone number, including area code:
(619) 929-9500




TABLE OF CONTENTS Item Page 1. Changes in Control of Registrant. * 2. Acquisition or Disposition of Assets. 3 3. Bankruptcy or Receivership. * 4. Changes in Registrant's Certifying * Accountant. 5. Other Events. * 6. Resignations of Registrant's Directors. * 7. Financial Statements and Exhibits. (a) Financial statements of businesses 3 acquired. (b) Pro forma financial information. 3 (c) Exhibits. 3 Signatures 12
* No information provided due to inapplicability of item. Item 2. Acquisition or Disposition of Assets. On November 4, 1996, the Company acquired the New Drug Application and U.S. trademark for Ethamolin Injection (the "Ethamolin Assets") and the finished goods inventory on hand at closing from Schwarz Pharma, Inc., a Delaware corporation. The acquisition was accomplished in an arm's length negotiation through a purchase of assets and accounted for using the purchase method of accounting. The total purchase price was $3,286,642, of which the Company paid $2,086,642 in cash and issued a $1,200,000 note bearing interest at 8% per annum at closing. The principal and accrued interest on the note are due and payable on November 3, 1997. Repayment of the principal and interest on the note is secured by the Ethamolin Assets. The Company used its working capital to make the cash payment at closing. Item 7. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired. Index to the Financial Statements of Schwarz Pharma, Inc. Ethamolin Product Line Sequentiall Document y Numbered Page Financal Statements 4 ............................................ Report of Independent Auditors 6 ................................. Statement of Assets Acquired 7 ................................... Statement of Operating Revenue and Expenses Directly Related to Acquired Business 8 ....................... Notes to Financial Statements 9 ..................................
(b) Proforma financial information. Index to the Proforma Financial Statements of Cypros Pharmaceutical Corporation and Schwarz Pharma, Inc. Ethamolin Product Line Sequentiall Document y Numbered Page Proforma Condensed Balance Sheets and explanatory notes 10 ..................... Proforma Condensed Statements of Operations and explanatory notes 11 ......................
(c) Exhibits. None Financial Statements Schwarz Pharma, Inc. Ethamolin Product Line For the year ended July 31, 1996 Schwarz Pharma, Inc. Ethamolin Product Line Financial Statements For the year ended July 31, 1996 Contents Report of Independent Auditors 1 .................................. Statement of Assets Acquired 2 .................................... Statement of Operating Revenue and Expenses Directly Related to Acquired Business 3 .............................. Notes to Financial Statements 4 ...................................
Report of Ernst & Young LLP, Independent Auditors Board of Directors and Shareholders Schwarz Pharma, Inc. We have audited the accompanying statement of assets acquired of the Schwarz Pharma, Inc. Ethamolin Product Line (the Product Line) as of July 31, 1996, and the related statement of operating revenue and expenses directly related to the acquired business, for the year then ended. These financial statements are the responsibility of the Product LineOs management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. As described in Note 2, these financial statements were prepared solely to present the assets acquired by Cypros Pharmaceutical Corporation pursuant to a product line purchase agreement and are not intended to be a complete presentation of the Product Line's assets, operating revenues and expenses. In our opinion, the financial statements referred to above present fairly, in all material respects, the assets acquired of the Product Line at July 31, 1996, and its operating revenue and its expenses directly related to the acquired business for the year then ended. ERNST & YOUNG LLP San Diego, California November 27, 1996
Schwarz Pharma, Inc. Ethamolin Product Line Statement of Assets Acquired Year ended July 31, 1996 Assets Inventory $59,127 Total assets acquired $59,127
See accompanying notes.
Schwarz Pharma, Inc. Ethamolin Product Line Statement of Operating Revenue and Expenses Directly Related to Acquired Business Year ended July 31, 1996 Net sales $1,126,76 6 Cost of sales 142,116 Promotion/royalties 153 Excess of operating revenue over expenses directly $ related to acquired business 984,497
See accompanying notes. Schwarz Pharma, Inc. Ethamolin Product Line Notes to Financial Statements 1. Nature of Business Ethamolin is a product being distributed by Schwarz Pharma, Inc., a Delaware Corporation. Ethamolin is an acute-care injectable drug approved by the U.S. Food and Drug Administration for the treatment of bleeding esophageal varices. 2. Significant Accounting Policies Basis of Accounting The financial statements were prepared in accordance with Securities and Exchange Commission Rule 3-05 of Regulation S-X for acquired businesses not accounted for as a separate product line by the previous owner. Accordingly, the statement of assets acquired reflects only those assets purchased and does not include allocations for such items as intangible property, accounts receivable, accounts payable and debt. The statement of operating revenue and expenses directly related to the acquired business does not include allocations for overhead, selling and general administration expenses, interest expense and income taxes. Inventory Inventory consists entirely of finished goods and is valued at the lower of first-in, first-out cost or market value. 3. Significant Customers In 1996, approximately 84% of net sales was to three customers. 4. Subsequent Events On November 4, 1996, the Ethamolin product line was sold to Cypros Pharmaceutical Corporation, including all inventory on hand as of that date.
Cypros Pharmaceutical Corporation PROFORMA CONDENSED BALANCE SHEETS July 31, 1996 The Ethamoli n Product Line Cypros of Pharmaceuti Schwarz cal Corporation Pharma, Proforma Proforma Inc. Adjustments Adjusted ASSETS Cash and cash $ $ - (1) $6,220,062 equivalents 8,306,752 $(2,086,690 ) Short-term 7,690,297 - - 7,690,297 investments Purchased (2) technology, net 2,629,427 - 3,214,048 5,843,475 (3) Other assets 1,120,038 59,127 13,515 1,192,680 Total Assets $ $59,127 $ 19,746,514 1,140,873 $20,946,514 LIABILITIES AND SHAREHOLDER EQUITY S' Total liabilities $ $ - $ (4) $2,436,064 1,236,064 1,200,000 Shareholders' equity: Common stock - - 21,838,493 21,838,493 Mandatorily convertible notes 7,458,498 - - 7,458,498 Deferred compensation - - (304,309) (304,309) Retained earnings/ - - (10,482,232 (Accumulated (10,482,232 ) deficit) ) Total shareholders' equity - - 18,510,450 18,510,450 Total liabilities and shareholders' $ $ - $ $20,946,514 equity 19,746,514 1,200,000
(1) Assumes that the transaction closed on July 31, 1996 and represents the value of cash consideration paid at closing for Ethamolin. (2) Represents the full price of the acquisition, including a $1,200,000 promissory note issued to Schwarz Pharma, Inc. at closing (the "Note"), net of the Ethamolin inventory received at closing. This asset will be amortized by the Company over seven (7) years. (3) Represents the value of Ethamolin inventory acquired at closing. (4) Represents the Company's obligation to pay the Note.
Cypros Pharmaceutical Corporation PROFORMA CONDENSEDSTATEMENTS OF OPERATIONS Year Ended July 31, 1996 The Ethamolin Cypros Product Line Pharmaceuti of Schwarz Proforma Proforma cal Corporation Pharma, Adjustmen Adjusted Inc. ts > Sales $ $ $ $ 1,275,240 1,126,766 - 2,402,006 Cost of Goods Sold 405,142 142,116 - 547,258 Gross Margin 870,098 984,650 1,854,748 Selling, general and administrative 2,597,054 153 458,997 (1 3,056,204 ) Clinical testing and regulatory 1,389,128 - - 1,389,128 Research and development 1,002,226 - - 1,002,226 Income (Loss) from operations (4,118,310) 984,497 (3,592,810 ) Other income (expense): Research grant 270,510 - - 270,510 income Interest income, 757,692 - (210,768) (2 642,924 net ) Net Loss $ $ $ $(2,679,37 (3,090,108) 984,497 344,229 6) Loss per share $ $ (0.27) (0.23) Weighted average shares outstanding 11,518,169 11,518,169
(1) Represents the substitution of the historical selling, general and administrative expenses for the amortization of purchased technology for the year ended July 31, 1996. (2) Represents the decrease in interest income resulting from an assumed closing of the transaction at the beginning of the year instead of at the end of the year, and thus, less funds available for investment during the year. Also includes $96,000 of interest expense related to the Note. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, County of San Diego, State of California, on the 16th day of January, 1997. CYPROS PHARMACEUTICAL CORPORATION (Signature) David W. Nassif Vice President, Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)